Several other research firms have also commented on CLLS. ValuEngine raised Cellectis from a hold rating to a buy rating in a research report on Tuesday, September 18th. BidaskClub raised Cellectis from a sell rating to a hold rating in a research report on Saturday, October 6th. Finally, Zacks Investment Research raised Cellectis from a hold rating to a buy rating and set a $25.00 price objective on the stock in a research report on Friday, November 16th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus price target of $48.00.
NASDAQ:CLLS opened at $21.08 on Friday. Cellectis has a 12 month low of $20.15 and a 12 month high of $38.85. The stock has a market capitalization of $877.04 million, a price-to-earnings ratio of -7.58 and a beta of 1.76.
Cellectis Company Profile
Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).
See Also: Dollar Cost Averaging
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.